Over the last 7 days, the United States market has risen by 4.4%, and in the past year, it has climbed an impressive 32%, with earnings expected to grow by 16% annually. While penny stocks might seem like a relic from earlier market times, they continue to represent smaller or less-established companies that can offer significant value when chosen wisely. By focusing on those with strong financials and clear growth potential, investors can uncover opportunities in these niche stocks that may provide both stability and upside potential.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Rewards & Risks
WM Technology (MAPS)	$0.36	$64.14M	✅ 3 ⚠️ 5 View Analysis >
LexinFintech Holdings (LX)	$2.25	$385.32M	✅ 3 ⚠️ 2 View Analysis >
Tuniu (TOUR)	$0.7287	$84.7M	✅ 2 ⚠️ 2 View Analysis >
Information Services Group (III)	$3.11	$194.51M	✅ 3 ⚠️ 1 View Analysis >
Golden Growers Cooperative (GGRO.U)	$5.00	$77.45M	✅ 2 ⚠️ 5 View Analysis >
Niagen Bioscience (NAGE)	$4.69	$369.94M	✅ 3 ⚠️ 1 View Analysis >
LifeVantage (LFVN)	$4.135	$53.4M	✅ 4 ⚠️ 3 View Analysis >
SIGA Technologies (SIGA)	$7.80	$319.53M	✅ 2 ⚠️ 1 View Analysis >
BAB (BABB)	$0.909	$6.36M	✅ 2 ⚠️ 3 View Analysis >
Marine Petroleum Trust (MARP.S)	$5.00	$10.28M	✅ 2 ⚠️ 4 View Analysis >

We're going to check out a few of the best picks from our screener tool.

Niagen Bioscience (NAGE)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Niagen Bioscience, Inc. is a bioscience company focused on developing healthy aging products, with a market cap of $369.94 million.

Operations: The company's revenue is derived from three segments: Ingredients ($28.68 million), Consumer Products ($97.67 million), and Analytical Reference Standards and Services ($3.08 million).

Market Cap: $369.94M

Niagen Bioscience, Inc., with a market cap of US$369.94 million, has demonstrated significant growth and stability as a penny stock. The company has achieved profitability over the past five years, with earnings growing by 64.2% annually and an impressive 103.3% increase over the past year alone. Its strong financial position is highlighted by high return on equity (22.7%) and no debt obligations, while its short-term assets exceed long-term liabilities significantly. Recent strategic partnerships, such as with OneSpaWorld for Niagen IV distribution on cruise ships, indicate expanding market reach and potential revenue growth opportunities in health and wellness sectors.

Strata Critical Medical (SRTA)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Strata Critical Medical, Inc. operates in the United States, offering time-critical logistics and medical services to the healthcare industry, with a market cap of approximately $358.40 million.

Operations: The company generates revenue through its Clinical segment, contributing $20.35 million, and its Logistics segment, which accounts for $176.79 million.

Market Cap: $358.4M

Strata Critical Medical, Inc., with a market cap of US$358.40 million, is navigating the penny stock landscape by focusing on time-critical logistics and medical services. The company reported significant revenue growth, with full-year sales reaching US$197.14 million in 2025 compared to US$146.82 million the previous year, although it remains unprofitable with a negative return on equity (-7.19%). Despite this, Strata's short-term assets (US$126.20 million) comfortably cover both its short- and long-term liabilities, and it has secured an asset-based revolving credit facility of up to US$50 million for working capital needs.

Lineage Cell Therapeutics (LCTX)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing cell replacement therapies for serious medical conditions, with a market cap of $376.12 million.

Operations: The company's revenue is primarily derived from its research and development of therapeutic products, amounting to $14.56 million.

Market Cap: $376.12M

Lineage Cell Therapeutics, Inc., with a market cap of US$376.12 million, is advancing its cell replacement therapies using the AlloSCOPE platform to manufacture scalable, off-the-shelf products. While unprofitable and reporting a net loss of US$63.53 million in 2025, the company has no debt and sufficient cash runway for over a year. Recent strategic moves include forming a Scientific Advisory Board and expanding its pipeline with new programs like COR1 for corneal endothelial disease. The collaboration with Roche's Genentech on OpRegen highlights potential growth avenues in the regenerative medicine sector despite current financial challenges.

Summing It All Up

• Take a closer look at our US Penny Stocks list of 357 companies by clicking here.
• Curious About Other Options? Explore 24 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.